Autolus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Autolus Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 49.1% bzw. 55.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -193.6% betragen.

Wichtige Informationen

49.1%

Wachstumsrate der Gewinne

55.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.8%
Wachstumsrate der Einnahmen	55.5%
Zukünftige Eigenkapitalrendite	-193.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	02 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AUTL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	175	-91	-62	-43	6
12/31/2025	61	-183	-137	-134	8
12/31/2024	15	-208	-189	-137	8
6/30/2024	10	-234	-161	-157	N/A
3/31/2024	10	-221	-152	-144	N/A
12/31/2023	2	-208	-157	-146	N/A
9/30/2023	6	-158	-145	-135	N/A
6/30/2023	7	-155	-142	-127	N/A
3/31/2023	7	-152	-133	-120	N/A
12/31/2022	6	-149	-123	-112	N/A
9/30/2022	3	-164	-119	-107	N/A
6/30/2022	1	-155	-119	-110	N/A
3/31/2022	2	-146	-123	-116	N/A
12/31/2021	2	-142	-127	-118	N/A
9/30/2021	3	-143	-149	-136	N/A
6/30/2021	3	-147	-154	-141	N/A
3/31/2021	2	-145	-145	-131	N/A
12/31/2020	2	-142	-132	-118	N/A
9/30/2020	2	-140	-134	-123	N/A
6/30/2020	1	-130	-120	-109	N/A
3/31/2020	1	-127	-113	-99	N/A
12/31/2019	3	-124	-120	-101	N/A
9/30/2019	3	-104	-109	-88	N/A
6/30/2019	3	-89	-93	-72	N/A
3/31/2019	3	-68	-76	-61	N/A
12/31/2018	1	-58	-56	-43	N/A
9/30/2018	1	-45	-41	-32	N/A
6/30/2018	1	-41	N/A	N/A	N/A
3/31/2018	2	-38	N/A	N/A	N/A
12/31/2017	2	-29	N/A	N/A	N/A
9/30/2017	2	-20	N/A	-16	N/A
9/30/2016	1	-13	N/A	-10	N/A
9/30/2015	0	-7	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AUTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AUTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AUTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AUTLDie Einnahmen des Unternehmens (55.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: AUTLDie Einnahmen des Unternehmens (55.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AUTL wird voraussichtlich in 3 Jahren unrentabel sein.

Autolus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 15%

Consensus revenue estimates decrease by 24%, EPS upgraded

Consensus revenue estimates increase by 23%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 11%

Consensus estimates of losses per share improve by 10%

Recent updates

Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024

Founder notifies of intention to sell stock

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting

Consensus revenue estimates fall by 15%

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

High number of new directors

Autolus Therapeutics: Major Inflection Point On The Horizon

Autolus Therapeutics plc to Report Q2, 2024 Results on Aug 08, 2024

Autolus Therapeutics plc to Present Three Clinical Data Updates on Obecabtagene Autoleucel (obe-cel) in Relapsed/Refractory B-Cell Acute L-Cell Acute Lymphoblastic Leukemia (All) Patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2024

Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO

Autolus Therapeutics plc announced delayed 10-Q filing

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

High number of new directors

Autolus Therapeutics plc to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Autolus Therapeutics Announces Changes to its Board of Directors

New major risk - Shareholder dilution

Consensus revenue estimates increase by 23%

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.57 loss in FY 2022)

Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site

Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site

Autolus Therapeutics plc to Report Fiscal Year 2023 Results on Mar 14, 2024

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Autolus Therapeutics plc has completed a Follow-on Equity Offering in the amount of $350.000016 million.

Autolus Therapeutics plc announced that it expects to receive $220.000002 million in funding from BioNTech SE

High number of new directors

Consensus revenue estimates decrease by 11%

Autolus Therapeutics plc Announces Acceptance of Biologics License Application for Obecabtagene Autoleucel as Potential Treatment for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Autolus Therapeutics plc Announces the Appointment of Robert W. Azelby to Its Board of Directors

Autolus Therapeutics plc Announces Changes to Its Board of Directors, Effective December 31, 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Consensus estimates of losses per share improve by 10%

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Consensus revenue estimates increase by 11%

Autolus Therapeutics plc to Report Q3, 2023 Results on Nov 02, 2023

Price target increased by 9.1% to US$7.98

Autolus Therapeutics plc Announces Data from Auto1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood

Autolus Therapeutics plc Announces CFO Changes

Autolus Therapeutics Announces Publication in Nature Medicine on Obe-Cel in Pediatric Acute Lymphoblastic Leukemia

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Autolus Therapeutics plc Appoints Robert Iannone as Non-Executive Director

Autolus Therapeutics plc Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Autolus Therapeutics plc, Annual General Meeting, Jun 30, 2023

Consensus EPS estimates upgraded to US$0.87 loss

Autolus Therapeutics plc Presents Positive Results from Pivotal Phase 2 Felix Study in Adult R/R B-All At Asco

Consensus revenue estimates decrease by 55%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 65%

Consensus revenue estimates decrease by 90%, EPS upgraded

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Autolus Therapeutics plc to Report Q4, 2022 Results on Mar 07, 2023

Autolus Therapeutics plc Announces Board Changes

Consensus forecasts updated

Price target decreased to US$9.40

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Consensus revenue estimates increase by 281%

Autolus Therapeutics plc Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis

Price target decreased to US$10.19

Consensus revenue estimates increase by 979%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Autolus Therapeutics plc to Report Q3, 2022 Results on Nov 03, 2022

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Consensus revenue estimates fall by 40%

Price target decreased to US$10.19